Editas Medicine, Inc. (EDIT) return on equity (ROE)

Return on equity · fiscal 2025
-586.6%

Editas Medicine, Inc. (EDIT) earned a return on equity of -586.6% in fiscal 2025 (the year ended December 31, 2025). That is 410.0 percentage points lower than the -176.6% of fiscal 2024. Figures as of 17 Nov 2026, 20:44 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-586.6%
Change on fiscal 2024
−410.0 pts
Highest on record
-29.5%fiscal 2020
Lowest on record
-586.6%fiscal 2025
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Editas Medicine, Inc. return on equity (ROE), in more detail

Across the 10 fiscal years on record (2016–2025), the highest was -29.5% in fiscal 2020 and the lowest -586.6% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 9 earlier fiscal years on record, whose median is -51.0%.

History · 10 fiscal years

Return on equity by fiscal year

Editas Medicine, Inc. return on equity (ROE), year by year

Editas Medicine, Inc. (EDIT) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-586.6% 410.0 pts down
2024-176.6% 132.7 pts down
2023-43.9% 17.2 pts up
2022-61.1% 26.3 pts down
2021-34.8% 5.3 pts down
2020-29.5% 21.5 pts up
2019-51.0% 4.4 pts down
2018-46.6% 11.3 pts up
2017-57.8% 14.4 pts up
2016-72.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on EDIT

Editas Medicine, Inc., figure by figure

Editas Medicine, Inc. (EDIT) overview: price, valuation and scorecard

Editas Medicine, Inc. return on equity (ROE): questions and answers

What is Editas Medicine, Inc.'s return on equity?

Editas Medicine, Inc. (EDIT) earned a return on equity of -586.6% in fiscal 2025 (the year ended December 31, 2025). That is 410.0 percentage points lower than the -176.6% of fiscal 2024.

Is Editas Medicine, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 9 earlier fiscal years on record, whose median is -51.0%.

What are the highest and lowest return on equity figures on record for Editas Medicine, Inc.?

Across the 10 fiscal years on record (2016–2025), the highest was -29.5% in fiscal 2020 and the lowest -586.6% in fiscal 2025.

How is Editas Medicine, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Editas Medicine, Inc. (EDIT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/EDIT/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.